Mangoceuticals (MGRX) Payables (2022 - 2026)

Mangoceuticals has disclosed Payables across 5 years of filings, most recently posting $529800.0 for Q1 2026.

• Payables for Q1 2026 came in at $529800.0, down 55.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $529800.0 (down 55.03% YoY), and the FY2025 annual result was $416682.0, down 57.8% from the prior year.
• Payables came in at $529800.0 for Q1 2026 at Mangoceuticals, up from $416682.0 in the prior quarter.
• In the past five years, Payables ranged from a high of $1.2 million in Q1 2025 to a low of $30796.0 in Q1 2023.
• The 5-year median for Payables is $278723.5 (2023), against an average of $428391.1.
• Peak annual rise in Payables reached 1249.96% in 2025, while the deepest fall reached 57.8% in 2025.
• Mangoceuticals' Payables stood at $111935.0 in 2022, then rose by 25.76% to $140765.0 in 2023, then jumped by 601.52% to $987501.0 in 2024, then tumbled by 57.8% to $416682.0 in 2025, then advanced by 27.15% to $529800.0 in 2026.
• The last three Payables figures came in at $529800.0 (Q1 2026), $416682.0 (Q4 2025), and $626964.0 (Q3 2025), per Business Quant data.